Coronavirus

Invivyd announced its product, pemivibart (Pemgarda), has continued to show consistent neutralization for almost 3 years, with no meaningful change to activity.

The continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.

A survey of this population showed that over a 2 and ½ year period, there was a decrease in post-acute sequelae of SARS-CoV-2 infection (PASC). However, 1% of respondents said they are still dealing with restrictions in their lives.

A case series of 13 patients suggests that extended courses of Paxlovid could benefit some Long COVID patients, but the results are inconsistent.

Recent study highlights Paxlovid’s ability to reduce hospitalizations and mortality in high-risk populations, but underscores the need for personalized treatment.

Charlotte Allerton explains how ibuzatrelvir, a second-generation treatment, could reduce drug interactions and taste disturbances compared to PAXLOVID, offering a simplified approach for high-risk patients.

6.4% of US adults experience Long COVID, with 19.8% reporting significant activity limitations, while the updated RECOVER study refines the classification index.

Navigating the long road of Long COVID involves more than recovering from an infection; it requires specialized, multifaceted care to address ongoing and often invisible neurological symptoms.

The 2 companies will examine molnupiravir (Lagevrio) using a different formulation that is not approved in any country globally.

New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential treatment strategies.

New therapeutics offer some hope in this emerging market.

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.

The CANOPY Phase 3 clinical trial demonstrated a reduced risk of symptomatic COVID-19, including a 64% reduction during the off-drug follow-up period.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.

A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.

Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.

A single dose of the mRNA-1273.222 vaccine demonstrated strong immune responses against various omicron subvariants and showed a favorable safety profile compared to existing vaccines.

Study finds this population saw a 45% reduction of ongoing symptoms in those with COVID-19 weeks later and who had received subsequent doses of the original monovalent vaccine.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

New research highlights a complex relationship between COVID-19 and cognitive function, suggesting that even mild infections can lead to subtle memory and attention deficits lasting at least a year.

The study estimates that vaccination efforts may have averted between 610,000 and 2.61 million deaths during the first 18 months of the rollout.

Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.

A large study shows a moderate benefit to taking the antimalarial therapy.

Adults with type 2 diabetes who use metformin have a 13% to 21% reduced risk of developing Long COVID or dying from COVID-19 compared to those taking other diabetes medications.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

Females are more frequently affected by Long COVID than males, highlighting distinct immunological processes and hormonal variations.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.